Skip to main content

Inflammation

25
Pipeline Programs
30
Companies
50
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
10
1
3
0
5
6
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
2100%
+ 66 programs with unclassified modality

Competitive Landscape

34 companies ranked by most advanced pipeline stage

Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
3 programs
1
1
BromfenacPhase 41 trial
MapracoratPhase 31 trial
Fluocinolone Acetonide 0.59 mgN/A1 trial
Active Trials
NCT01060787Completed98Est. Jun 2019
NCT01298752Terminated177Est. Nov 2011
NCT01310127Completed23Est. May 2011
Bausch + Lomb
Bausch + LombNJ - Bridgewater
2 programs
1
1
BromfenacPhase 4
MapracoratPhase 3
Laurent Pharmaceuticals
1
Eicosapentaenoic acid monoglyceridPhase 41 trial
Active Trials
NCT04897893Completed30Est. Sep 2023
Integrated Biosciences
Integrated BiosciencesCA - San Carlos
1 program
1
Eicosapentaenoic acid monoglyceridPhase 4
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
Ketorolac 0.4%Phase 41 trial
Active Trials
NCT00791323Completed9Est. Aug 2009
Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
1 program
1
tart cultivar Montmorency cherry juicePhase 41 trial
Active Trials
NCT01547949Completed15Est. Jul 2012
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
2 programs
1
Arm 2: cholecalciferol 50,000 IUPhase 31 trial
Philips stoveN/A1 trial
Active Trials
NCT04633135Completed200Est. Dec 2017
NCT02920502Completed24Est. Aug 2015
Alloksys Life Sciences
Alloksys Life SciencesNetherlands - Wageningen
1 program
1
bIAP bolus and 8h infusionPhase 31 trial
Active Trials
NCT01144611Completed53Est. Dec 2013
Ache Laboratorios Farmaceuticos
1
diphenhydramine + dropropizine + pseudoephedrinePhase 31 trial
Active Trials
NCT01177852Withdrawn0
CSL Seqirus
CSL SeqirusUK - Maidenhead
1 program
1
ClazakizumabPhase 2Monoclonal Antibody
Resolve Therapeutics
1
RX-10045Phase 21 trial
Active Trials
NCT02329743Completed256Est. Sep 2015
VivaVision Biotech
VivaVision BiotechChina - Shanghai
1 program
1
VVN461 Ophthalmic Solution 1.0%Phase 21 trial
Active Trials
NCT06164743Completed91Est. May 2024
Angeles Therapeutics
1
1
VB-201Phase 1/21 trial
NaproxenPhase 11 trial
Self-Focused Acts of Kindness InterventionN/A1 trial
Active Trials
NCT03322397Completed97Est. Jan 2019
NCT03771612Completed144Est. Jun 2024
NCT04939311Withdrawn0Est. Jul 2027
Human BioSciences
1
InulinPhase 11 trial
Breakfast meal with placebo powderN/A1 trial
Cherry consumptionN/A1 trial
ChokeberryN/A1 trial
High saturated fat meal, placebo powder and sunflower oilN/A1 trial
Active Trials
NCT01594008Completed43Est. May 2013
NCT01734070Completed20Est. Sep 2004
NCT05410327Completed46Est. Jan 2023
+2 more trials
Sandoz
SandozAustria - Kundl
4 programs
2
Diclofenac Sodium 50 mg TabletsPhase 11 trial
Diclofenac Sodium 50 mg Tablets Under Fasting ConditionsPhase 11 trial
Diclofenac Sodium 75 mg Tablets Under Fasting ConditionsPHASE_11 trial
Indomethacin 75mg Extended-Release Capsules, SandozPHASE_11 trial
Active Trials
NCT00913887Completed18Est. May 1994
NCT00858195Completed36Est. Jul 2006
NCT00913224Completed38Est. Apr 1993
+1 more trials
Medtronic
MedtronicNJ - Phillipsburg
2 programs
1
Vagal Nerve StimulationPhase 11 trial
Inflammation and Glycation in a General Adult PopulationN/A1 trial
Active Trials
NCT01796184Completed1,516Est. Mar 2015
NCT01944228Completed22Est. Oct 2013
ViiV Healthcare
ViiV HealthcareNC - Durham
2 programs
2
CantharidinPhase 1
Cantharidin solutionPhase 1
Bayer
BayerLEVERKUSEN, Germany
1 program
1
BAY1834845Phase 11 trial
Active Trials
NCT03244462Completed10Est. Jul 2018
Innate Pharma
Innate PharmaFrance - Marseille
1 program
1
NNC 0141-0000-0100Phase 11 trial
Active Trials
NCT01370902Completed92Est. Mar 2014
Pfizer
PfizerNEW YORK, NY
1 program
1
aldosteronePhase 11 trial
Active Trials
NCT00700479Completed20Est. Jun 2008
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
18 programs
NNC 0151-0000-0000PHASE_11 trial
NNC 0151-0000-0000PHASE_11 trial
NNC0114-0000-0005PHASE_11 trial
NNC0114-0006PHASE_11 trial
NNC0114-0006PHASE_11 trial
+13 more programs
Active Trials
NCT02151409Completed60Est. Oct 2009
NCT01018238Withdrawn0Est. Nov 2009
NCT01208506Completed64Est. Feb 2012
+15 more trials
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
3 programs
Analysis of Bronchial Tissue and Fluid in Patients With Wegener's GranulomatosisN/A1 trial
Blood Markers of Inflammation, Blood Clotting and Blood Vessel Function in HIV-infected AdultsN/A1 trial
Evaluation and Long-Term Follow-up of Patients With Inflammatory DisordersN/A1 trial
Active Trials
NCT00001541Completed25Est. Jan 2003
NCT00776412Completed310
NCT00001351Enrolling By Invitation500
Innovation Pharmaceuticals
1 program
CEAGN/A1 trial
Active Trials
NCT03906825Completed80Est. Aug 2018
Eppendorf
EppendorfGermany - Hamburg
1 program
CytoSorb cytokine eliminationN/A
CytoSorbents
CytoSorbentsPRINCETON, NJ
1 program
CytoSorb cytokine eliminationN/A1 trial
Active Trials
NCT02606799Terminated5Est. Apr 2017
Medica Corp
Medica CorpMA - Bedford
1 program
Nasal swabN/A1 trial
Active Trials
NCT03311048Completed167Est. Dec 2017
Philips
PhilipsNetherlands - Amsterdam
1 program
Sonicare/Elite-Flexcare ToothbrushN/A1 trial
Active Trials
NCT02187185Completed175Est. Mar 2012
Lundbeck
LundbeckDenmark - Copenhagen
1 program
TNF-alphaN/A1 trial
Active Trials
NCT01452958Completed24Est. Jan 2013
UNION therapeutics
The Prognosis of Patients After PCI:a Multi-center Study in ChinaN/A
Autonomous Therapeutics
1 program
The Prognosis of Patients After PCI:a Multi-center Study in ChinaN/A1 trial
Active Trials
NCT05614050Recruiting2,400Est. Nov 2027

+4 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Laurent PharmaceuticalsEicosapentaenoic acid monoglycerid
Oregon Therapeuticstart cultivar Montmorency cherry juice
Bausch HealthBromfenac
AbbVieKetorolac 0.4%
Colorado TherapeuticsArm 2: cholecalciferol 50,000 IU
Ache Laboratorios Farmaceuticosdiphenhydramine + dropropizine + pseudoephedrine
Bausch HealthMapracorat
Alloksys Life SciencesbIAP bolus and 8h infusion
VivaVision BiotechVVN461 Ophthalmic Solution 1.0%
CSL BehringClazakizumab
Resolve TherapeuticsRX-10045
Novo NordiskNNC0109-0012
Novo NordiskNNC0114-0006
Novo NordiskNNC0109-0012
Novo Nordiskcatridecacog

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 6,938 patients across 50 trials

NCT04897893Laurent PharmaceuticalsEicosapentaenoic acid monoglycerid

Impact of 2.0g Daily of MAG-EPA on the AA/EPA Ratio and Inflammation Biomarkers in a Healthy Population Aged of 50+.

Start: Apr 2021Est. completion: Sep 202330 patients
Phase 4Completed
NCT01547949Oregon Therapeuticstart cultivar Montmorency cherry juice

Efficacy of Tart Cherry Juice in Reducing Muscle Injury and Biomarkers of Muscle Damage Among Healthy Adults

Start: Mar 2012Est. completion: Jul 201215 patients
Phase 4Completed

Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1%

Start: Nov 2010Est. completion: May 201123 patients
Phase 4Completed
NCT00791323AbbVieKetorolac 0.4%

Efficacy of Ketorolac 0.4% in Prostaglandin Suppression

Start: Nov 2008Est. completion: Aug 20099 patients
Phase 4Completed
NCT02920502Colorado TherapeuticsArm 2: cholecalciferol 50,000 IU

Effect of a One Time Dose of Cholecalciferol on Serum Concentration of 25-Hydroxyvitamin D and Macrophages

Start: Jun 2013Est. completion: Aug 201524 patients
Phase 3Completed
NCT01177852Ache Laboratorios Farmaceuticosdiphenhydramine + dropropizine + pseudoephedrine

Evaluation of Efficacy and Safety in Control Cough and the Relief of Nasal Symptoms in Children 2-12 Years Old,Suffering From Cough and Acute Rhinitis

Start: Oct 20110
Phase 3Withdrawn

Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation Following Cataract Surgery

Start: Feb 2011Est. completion: Nov 2011177 patients
Phase 3Terminated
NCT01144611Alloksys Life SciencesbIAP bolus and 8h infusion

Efficacy and Safety of Bovine Intestinal Alkaline Phosphatase (bIAP) During Heart Surgery

Start: Apr 2010Est. completion: Dec 201353 patients
Phase 3Completed
NCT06164743VivaVision BiotechVVN461 Ophthalmic Solution 1.0%

Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery

Start: Jan 2024Est. completion: May 202491 patients
Phase 2Completed

Improving Physical Function in Older Adults Using an Anti-inflammation Drug: The RIGHT Study

Start: Aug 2023Est. completion: Jul 202629 patients
Phase 2Active Not Recruiting

Efficacy and Safety of RX-10045 Ophthalmic Solution for Ocular Inflammation and Pain in Cataract Surgery

Start: Dec 2014Est. completion: Sep 2015256 patients
Phase 2Completed

A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Start: Sep 2014Est. completion: Sep 20150
Phase 2Withdrawn

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease

Start: Feb 2013Est. completion: Dec 201453 patients
Phase 2Completed

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

Start: Oct 2012Est. completion: Nov 2014298 patients
Phase 2Terminated

A Placebo-controlled Trial With rFXIII Administered to Subjects With Mild to Moderate Active Ulcerative Colitis

Start: Oct 2012Est. completion: Jul 201320 patients
Phase 2Terminated

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy of NNC0114-0006 in Subjects With Active Rheumatoid Arthritis

Start: Sep 2012Est. completion: Aug 201362 patients
Phase 2Completed

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Start: Aug 2012Est. completion: Nov 2014239 patients
Phase 2Terminated

Efficacy of NNC109-0012 in Subjects With Active Rheumatoid Arthritis

Start: Feb 2011Est. completion: Jan 201267 patients
Phase 2Completed
NCT01223911Novo NordiskNNC 0151-0000-0000

A Multiple Dose Trial of NNC 0151-0000-0000 in Subjects With Rheumatoid Arthritis

Start: Jan 2011Est. completion: Feb 201334 patients
Phase 2Completed

Immunomodulation Using VB-201 to Reduce Arterial Inflammation in Treated HIV - VITAL HIV Trial

Start: Jul 2022Est. completion: Jul 20270
Phase 1/2Withdrawn

WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study

Start: Sep 2022Est. completion: Jun 202560 patients
Phase 1Completed

Inflammation and Daily Life Study

Start: Feb 2022Est. completion: Jun 2024144 patients
Phase 1Completed

Food Effect, Oral & Intravenous Pharmacokinetics and Absolute Bioavailability of BAY1834845 Including Drug-drug Interaction With Methotrexate

Start: Aug 2017Est. completion: Jul 201810 patients
Phase 1Completed

A Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0215-0384 Administered to Subjects With Moderate to Severe Rheumatoid Arthritis

Start: Sep 2013Est. completion: Oct 201424 patients
Phase 1Completed
NCT01944228MedtronicVagal Nerve Stimulation

Effects of Transvenous Vagus Nerve Stimulation on Immune Response: a Pilot Study

Start: Aug 2013Est. completion: Oct 201322 patients
Phase 1Completed

An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE)

Start: Sep 2012Est. completion: Feb 201410 patients
Phase 1Terminated

First Human Dose Trial of NNC0215-0384 in Subjects With Rheumatoid Arthritis

Start: Jun 2012Est. completion: Jun 201336 patients
Phase 1Completed

Safety and Tolerability of NNC0114-0006 at Increasing Dose Levels in Subjects With Rheumatoid Arthritis

Start: Mar 2012Est. completion: Oct 201332 patients
Phase 1Completed
NCT01370902Innate PharmaNNC 0141-0000-0100

Safety and Tolerability of NNC0141-0000-0100 in Subjects With Rheumatoid Arthritis

Start: May 2011Est. completion: Mar 201492 patients
Phase 1Completed
NCT01208506Novo NordiskNNC0114-0000-0005

First-in-Man Trial of NNC114-0005 in Healthy Subjects and Subjects With Rheumatoid Arthritis

Start: Sep 2010Est. completion: Feb 201264 patients
Phase 1Completed

Safety and Tolerability of Anti-IL-20 in Subjects With Rheumatoid Arthritis

Start: Feb 2010Est. completion: Dec 201016 patients
Phase 1Completed
NCT01018238Novo NordiskNNC 0151-0000-0000

An Investigation of NNC 0151-0000-0000 in Subjects With Systemic Lupus Erythematosus (SLE)

Start: Nov 2009Est. completion: Nov 20090
Phase 1Withdrawn

Safety and Tolerability of Anti-IL-20 in Healthy Volunteers and Patients With Rheumatoid Arthritis

Start: Dec 2008Est. completion: Jan 201032 patients
Phase 1Completed
NCT02151409Novo NordiskNNC 0151-0000-0000

Dose-escalation Trial of Anti-C5aR Antibody in Healthy Subjects

Start: Jun 2008Est. completion: Oct 200960 patients
Phase 1Completed

First Human Dose Study of Anti-IL-20 in Psoriasis: A Study of Safety, Tolerability and Early Signals of Biologic and Clinical Effects

Start: Apr 2008Est. completion: Jan 201155 patients
Phase 1Terminated
NCT00858195SandozIndomethacin 75mg Extended-Release Capsules, Sandoz

A Relative Bioavailability Study of 75mg Indomethacin Extended-Release Capsules

Start: Jun 2006Est. completion: Jul 200636 patients
Phase 1Completed

Studies on Aldosterone and Vascular Function

Start: Jan 2006Est. completion: Jun 200820 patients
Phase 1Completed
NCT00913887SandozDiclofenac Sodium 75 mg Tablets Under Fasting Conditions

To Demonstrate the Relative Bioavailability of Diclofenac Sodium 75 mg Enteric-Coated Tablets Under Non-Fasting Conditions

Start: Apr 1994Est. completion: May 199418 patients
Phase 1Completed
NCT00914160SandozDiclofenac Sodium 50 mg Tablets Under Fasting Conditions

To Demonstrate the Relative Bioavailability of Diclofenac Sodium 50 mg Enteric-Coated Tablets Under Non-Fasting Conditions

Start: Aug 1993Est. completion: Sep 199318 patients
Phase 1Completed
NCT00913224SandozDiclofenac Sodium 50 mg Tablets

To Demonstrate the Relative Bioavailability of Diclofenac Sodium 50 mg Enteric-Coated Tablets

Start: Apr 1993Est. completion: Apr 199338 patients
Phase 1Completed
NCT05614050Autonomous TherapeuticsThe Prognosis of Patients After PCI:a Multi-center Study in China

The Prognosis of Patients After PCI:a Multi-center Study in China

Start: Nov 2022Est. completion: Nov 20272,400 patients
N/ARecruiting

Health Effects of Traditional Indigenous Chokeberry

Start: Jul 2022Est. completion: Jan 202346 patients
N/ACompleted

Effect of CEAG on Inflammation and Endothelial Function

Start: May 2018Est. completion: Aug 201880 patients
N/ACompleted
NCT03322397Angeles TherapeuticsSelf-Focused Acts of Kindness Intervention

Adolescent Acts of Kindness Intervention

Start: Oct 2017Est. completion: Jan 201997 patients
N/ACompleted
NCT02606799CytoSorbentsCytoSorb cytokine elimination

Extracorporeal Elimination of Cytokines Following Abdominal-thoracic Esophagectomy

Start: May 2016Est. completion: Apr 20175 patients
N/ATerminated
NCT01060787Bausch HealthFluocinolone Acetonide 0.59 mg

Evaluation of Corneal Endothelial Cell Density in Subjects Who Have Had a Fluocinolone Acetonide Implant

Start: Feb 2016Est. completion: Jun 201998 patients
N/ACompleted
NCT02472171Human BioSciencesHigh saturated fat meal, placebo powder and sunflower oil

Suppression of Postprandial Monocyte Activation by Blueberries or Docosahexaenoic Acid in Humans

Start: Jun 2015Est. completion: Nov 201762 patients
N/ACompleted

Airway Inflammatory Profile Among Cleaning Workers From Different Workplaces

Start: Feb 2015Est. completion: Dec 2017167 patients
N/ACompleted
NCT01796184MedtronicInflammation and Glycation in a General Adult Population

Inflammation and Glycation in a General Adult Population

Start: Nov 2012Est. completion: Mar 20151,516 patients
N/ACompleted

Research on Emissions, Air Quality, Climate and Cooking Technologies in Northern Ghana

Start: Jan 2012Est. completion: Dec 2017200 patients
N/ACompleted

Related Jobs

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

5 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 6,938 patients
30 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.